Higher-than-Expected Indirect Costs. The Prime Recipient understands that it is solely and exclusively responsible for managing its indirect costs. The Prime Recipient further understands that ARPA-E will not amend this Award solely to provide additional funds to cover increases in the Prime Recipient’s indirect cost rate. ARPA-E recognizes that the Prime Recipient may not be fully reimbursed for increases in its indirect cost rate, which may result in under-recovery. In the event that the Prime Recipient is not fully reimbursed for increases in its indirect cost rate, the Prime Recipient may use any under-recovery to meet its cost sharing obligations under this Award.
Higher-than-Expected Indirect Costs. The Recipient understands that it is solely and exclusively responsible for managing its indirect costs. The Recipient further understands that EERE will not amend this Award solely to provide additional funds to cover increases in the Recipient’s indirect cost rate. EERE recognizes that the Recipient may not be fully reimbursed for increases in its indirect cost rate, which may result in under-recovery. In the event that the Recipient is not fully reimbursed for increases in its indirect cost rate, the Recipient may use any under-recovery to meet its cost sharing obligations under this Award.
Higher-than-Expected Indirect Costs. The Prime Recipient understands that it is solely and exclusively responsible for managing its indirect costs. The Prime Recipient further understands that ARPA-E will not amend this Award solely to provide additional funds to cover increases in the Prime Recipient’s indirect cost rate. ARPA-E recognizes that the Prime Recipient may not be fully reimbursed for increases in its indirect cost rate, which may result in under-recovery. In the event that the Prime Recipient is not fully reimbursed for increases in its indirect cost rate, the Prime Recipient may use any under-recovery to meet its Phase II and Phase IIS cost sharing requirements under this Award. CLAUSE 31. PATENT COSTS Reimbursable Patent Costs Between Phase I, Phase II, and Phase IIS cumulatively, ARPA-E will reimburse the Prime Recipient up to $30,000 in for filing and prosecution of United States patent applications, including international applications (“PCT application”) submitted to the USPTO that are related to subject inventions disclosed to DOE in accordance with Attachment 2 to this Award. The Prime Recipient may request a waiver of the $30,000 reimbursement limit which is subject to review by the ARPA-E Program Director and approval by the Contracting Officer. Allowable costs associated with reporting subject inventions are not included in this $30,000 limitation.
Higher-than-Expected Indirect Costs. Recipients are expected to manage their indirect costs. EERE will not amend an award solely to provide additional funds for changes in indirect cost rates. EERE recognizes that the inability to obtain full reimbursement for indirect costs means the Recipient must absorb the under-recovery. Such under-recovery may be allocated as part of the organization’s required cost sharing.
Higher-than-Expected Indirect Costs. Recipients are expected to manage their indirect costs. EERE will not amend an award solely to provide additional funds for changes in indirect cost rates. EERE recognizes that the inability to obtain full reimbursement for indirect costs means the Recipient must absorb the under-recovery. EERE will not reimburse the Recipient for any final indirect costs that are in excess of the following designated indirect rate ceilings or specific amounts: [Insert ceilings or specific amounts]. In addition, the Recipient shall neither count costs in excess of the rate ceilings as cost share, nor allocate such costs to other Federally sponsored projects, unless approved by the Contracting Officer. This restriction does not apply to subrecipients’ indirect costs.
Higher-than-Expected Indirect Costs. The Prime Recipient understands that it is solely and exclusively responsible for managing its indirect costs. The Prime Recipient further understands that ARPA-E will not amend this Award solely to provide additional funds to cover increases in the Prime Recipient’s indirect cost rate. ARPA-E recognizes that the Prime Recipient may not be fully reimbursed for increases in its indirect cost rate, which may result in underrecovery. In the event that the Prime Recipient is not fully reimbursed for increases in its indirect cost rate, the Prime Recipient may use any underrecovery to meet its Phase II [and Phase IIS] cost sharing requirements under this Award. PRE-AWARD COSTS The Prime Recipient may incur pre-award costs up to ninety (90) days prior to the effective date of this Award and in an amount up to $20,000. Pre-award costs for periods preceding 90 days prior to the effective date of this Award or in excess of $20,000 are allowable only if approved in writing, prior to incurrence, by the DOE Contracting Officer. Any pre-award expenditures (including those made after DOE approval) are made at the Prime Recipient’s risk and do not impose any obligation on ARPA-E. Any pre-award costs claimed by the Prime Recipient will apply against the maximum obligation for Phase I detailed in Clause 20.
